Nomura Securities downgraded Biogen (NASDAQ: BIIB) from Buy to Neutral with a price target of $407.00 (from $378.00).Analyst M. Ian ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE